popdc2 Antibody

What are the primary applications for POPDC2 antibodies in cardiovascular research?

POPDC2 antibodies are primarily used in Western blotting (WB) and immunohistochemistry (IHC) applications for cardiovascular research. Based on validated antibody data, these applications provide insights into POPDC2's role in cardiac function regulation, particularly in heart rate dynamics mediated through cAMP-binding mechanisms .

For immunohistochemistry applications, POPDC2 antibodies typically work well at dilutions ranging from 1:200 to 1:500 for paraffin-embedded tissue sections, particularly effective for human heart muscle tissue . When applying POPDC2 antibodies for Western blotting, researchers should expect to detect a protein of approximately 42 kDa. Optimal results are achieved using cardiac tissue lysates prepared with Triton X-100-based lysis buffers supplemented with protease inhibitor cocktails .

How should tissue samples be prepared for optimal POPDC2 detection?

For optimal POPDC2 detection in tissue samples:

For immunohistochemistry:

• Mount sections on Superfrost glass slides

• For heart samples, sections should be mounted and subjected to immunohistochemistry using validated POPDC2 antibodies (such as HPA024255, Sigma-Aldrich)

• Detection is enhanced using Alexa Fluor 488-conjugated secondary antibodies (e.g., Alexa Fluor 488-conjugated donkey anti-rabbit, A21206)

• Counterstain with DAPI for nuclear visualization

• Image using confocal laser scanning microscopy (e.g., Zeiss LSM 780 AxioObserver with a plan-apochromat 20X/0.8 M27 objective)

For Western blotting:

• For ventricular tissue: excise, snap-freeze in liquid nitrogen, and pulverize with pre-cooled pestle and mortar

• Lyse tissue using 1% (v/v) Triton X-100-based lysis buffer followed by sonification

• Centrifuge lysates for 30 minutes at >16,000 g

• Use equal protein concentrations across all samples

How can I validate the specificity of my POPDC2 antibody?

POPDC2 antibody specificity can be validated through multiple approaches:

Genetic validation approach:

• Test antibody reactivity against wild-type tissue versus POPDC2 knockout (KO) tissue

• POPDC2 antibodies (e.g., Sigma HPA024255) have been tested with tissue sections from wild-type and POPDC2 null mutants, confirming non-reactivity in null mutant tissue

Epitope mapping approach:

• Select antibodies with well-defined target epitopes. For example, commercially available POPDC2 antibodies target different regions:

  • Antibodies targeting amino acids 200-350 (recombinant fragment protein)

  • Antibodies targeting the middle region (e.g., AA 218-267)

  • Antibodies targeting the full length (AA 1-364)

Western blot validation:

• Look for a single band at approximately 42 kDa

• Run comparative blots with positive control tissue (heart) and negative control tissue (tissues with low POPDC2 expression)

• Verify with recombinant POPDC2 protein as positive control

What controls are essential when working with POPDC2 antibodies?

When working with POPDC2 antibodies, include the following controls:

Negative controls:

• Tissue samples from POPDC2 knockout mice or POPDC2-deficient cell lines

• Isotype controls using non-specific IgG of the same species as the primary antibody

• Secondary antibody-only controls to assess non-specific binding

Positive controls:

• Heart tissue samples (ventricles), where POPDC2 is abundantly expressed

• Skeletal muscle samples for comparative analysis

• Recombinant POPDC2 protein (available from several sources with different reactivity profiles)

Competition controls:

• Pre-incubation of antibody with excess of the immunizing peptide/protein

• This has been demonstrated to reduce PLA signals in experiments between tagged POPDC1 and AC9

How can I optimize co-immunoprecipitation protocols for studying POPDC2 protein interactions?

Based on published protocols, optimize POPDC2 co-immunoprecipitation as follows:

Sample preparation:

• For tissue samples: lyse ventricular tissue using 1% (v/v) Triton X-100-based lysis buffer supplemented with protease inhibitor cocktail (e.g., cOmplete, Roche)

• Sonicate lysates and centrifuge for 30 minutes at >16,000 g

• Use equal protein concentrations across all samples

Immunoprecipitation procedure:

• Incubate cleared lysate overnight with a validated anti-POPDC2 antibody (e.g., HPA024255, Sigma-Aldrich)

• Capture antibodies using Protein A agarose

• Centrifuge, wash, then resuspend in appropriate sample buffer (e.g., NuPAGE LDS Sample Buffer)

• Incubate at 96°C for 5 minutes

• Remove remaining agarose by centrifugation

• Supplement sample with reducing agent (e.g., NuPAGE Sample Reducing Agent)

• Analyze by Western blotting

This protocol has been successfully used to detect POPDC1-POPDC2 interactions using a polyclonal goat anti-POPDC1 antibody (sc-49889, Santa Cruz Biotechnology) for detection .

What methods can I use to investigate POPDC2's role in cAMP signaling?

To investigate POPDC2's role in cAMP signaling, consider these validated approaches:

Proximity Ligation Assay (PLA):

• PLA can amplify detection of protein-protein interactions occurring within <60 nm

• Use appropriate primary antibodies against POPDC2 and potential interacting partners

• Visualize with fluorescent probes and confocal microscopy

• This approach has been used successfully to detect interactions between POPDC proteins and other cAMP signaling components

Bioluminescence Resonance Energy Transfer (BRET):

• Transfect cells with POPDC2 constructs containing C-terminal NanoLuc luciferase or HaloTag domains

• Add 100 nM HaloTag-618 dye 24 hours before measurement

• Include DMSO-only controls to determine background BRET signal

• Measure BRET 5 minutes after adding furimazine NanoLuc substrate using a luminometer

• Vary expression ratios by adjusting plasmid proportions during transfection

This approach has been validated for studying POPDC protein interactions and can be adapted for studying cAMP-dependent interactions .

cAMP binding assays:

• Radio-ligand binding studies with tritiated cAMP have demonstrated binding to the Popeye domain

• cAMP has been shown to inhibit 3H-cAMP binding to the Popeye domain with an IC50 of approximately 118nM

• This approach can determine if POPDC2 mutations affect cAMP binding affinity

How can I detect and characterize different POPDC2 mutant variants?

To detect and characterize POPDC2 mutant variants:

Site-directed mutagenesis approach:

• Use Q5 site-directed mutagenesis kit (NEB) to introduce clinically identified POPDC variants

• Design appropriate oligonucleotide primers for mutagenesis

• Insert mutated cDNAs into appropriate expression vectors (e.g., pECFP-N1/pEYFP-N1 for C-terminal fluorescent tagging)

• Verify mutations by sequencing

• Express in appropriate cell models (e.g., HEK293 cells)

Functional characterization:

• Assess membrane trafficking by quantitative fluorescence imaging

• Analyze protein-protein interactions using co-precipitation, proximity ligation, or BRET

• Evaluate cAMP binding properties using radio-ligand binding studies

• For ion channel modulation (e.g., TREK-1), perform electrophysiological studies

Imaging analysis for membrane trafficking:

• Outline plasma membrane using appropriate membrane marker (e.g., DiD)

• Define cytoplasmic area between inner edge of plasma membrane and nucleus

• Subtract background fluorescence from all images

• Determine fluorescence intensity within each compartment to quantify protein localization

What is the significance of the W188X mutation in POPDC2 and how can it be studied?

The W188X mutation in POPDC2 results in a premature stop codon at position 188, leading to deletion within the putative cAMP binding domain. Despite deleting the FQVT motif of the phosphate binding cassette (PBC), this mutation has shown peculiar characteristics:

Significance:

• Associated with limb-girdle muscular dystrophy and cardiac arrhythmia

• Unlike expected outcomes, cAMP responsiveness remains unaltered

• Interaction and modulation of TREK-1 current also remains unaltered

• Pathogenic mechanism is not fully understood but may involve altered kinetics of cAMP binding or interference with protein-protein interactions

Experimental approaches to study W188X:

• Expression systems: Generate constructs expressing W188X mutant POPDC2 with appropriate epitope tags for detection

• Protein interaction studies:

  • Co-immunoprecipitation to assess interaction with known partners

  • BRET analysis to quantify protein-protein interactions

  • Proximity ligation assay to visualize interactions in situ

• Membrane trafficking analysis:

  • Fluorescence microscopy with tagged constructs

  • Quantitative image analysis to assess membrane vs. cytoplasmic distribution

• Electrophysiology:

  • Patch-clamp studies to assess impact on TREK-1 channel function

  • Compare with other POPDC2 mutations for functional differences

• cAMP binding kinetics:

  • Radio-ligand binding studies with time-course analysis

  • Competition assays to determine binding affinities

What experimental approaches can effectively demonstrate POPDC2-TREK-1 interactions?

To effectively demonstrate POPDC2-TREK-1 interactions:

Co-expression and co-localization:

• Express fluorescently tagged POPDC2 and TREK-1 in heterologous expression systems

• Perform confocal microscopy to assess co-localization

• Quantify co-localization using appropriate image analysis software

Biochemical interaction:

• Perform co-immunoprecipitation using POPDC2 antibodies and detect TREK-1

• Perform reciprocal co-immunoprecipitation with TREK-1 antibodies and detect POPDC2

• Use appropriate controls including isotype control antibodies and samples lacking one of the interaction partners

Functional studies:

• Measure TREK-1 current in cells expressing POPDC2 compared to controls

• Assess cAMP-dependent modulation of the interaction:

  • Apply cAMP-elevating agents (e.g., forskolin, phosphodiesterase inhibitors)

  • Monitor changes in TREK-1 current or membrane localization

• Use patch-clamp electrophysiology to directly measure TREK-1 current density

These approaches have demonstrated that POPDC2 increases TREK-1 channel density at the plasma membrane and enhances K+ currents, with dissociation of the complex upon cAMP binding to POPDC proteins .

How can I investigate the role of POPDC2 in adenylyl cyclase 9 (AC9) signaling complexes?

To investigate POPDC2's role in AC9 signaling complexes:

Proximity Ligation Assay (PLA):

• Express YFP-tagged AC9 and POPDC2-MYC in appropriate cells (e.g., HEK293)

• Perform PLA using anti-tag antibodies or specific protein antibodies

• Include positive controls (e.g., AC9-Gβγ interactions)

• Include competition controls with non-tagged proteins to validate specificity

• Quantify PLA puncta using imaging software

Co-immunoprecipitation from cardiomyocytes:

• Isolate primary cardiomyocytes from appropriate models

• Infect with adenoviruses expressing tagged proteins of interest

• Perform co-immunoprecipitation using antibodies against specific tags or endogenous proteins

• Use Western blotting to detect interaction partners

• Include appropriate controls (e.g., GFP-expressing vectors)

Functional analysis of signaling complex:

• Generate knockout models (e.g., AC9 knockout mice)

• Measure phenotypic outcomes (e.g., bradycardia, heart rate variability)

• Compare with POPDC2 knockout phenotypes

• Assess TREK-1-associated adenylyl cyclase activity in heart tissue

• Perform rescue experiments with wild-type and mutant constructs

These approaches have revealed that POPDC1 acts as a novel adaptor for AC9 interactions with TREK-1 to regulate heart rate control, with implications for POPDC2's similar function in this complex .

How can I address non-specific binding issues with POPDC2 antibodies?

When encountering non-specific binding with POPDC2 antibodies:

Optimization strategies:

• Antibody selection:

  • Choose antibodies with validated specificity (e.g., Sigma HPA024255 or Abcam ab224121)

  • Consider antibodies targeting different epitopes if one region shows cross-reactivity

  • Compare polyclonal vs. monoclonal antibodies for your application

• Blocking optimization:

  • Extend blocking time (1-2 hours at room temperature or overnight at 4°C)

  • Test different blocking reagents (BSA, non-fat dry milk, normal serum)

  • Consider adding 0.1-0.3% Triton X-100 to reduce background in IHC

• Antibody dilution:

  • Test a range of antibody dilutions (e.g., 1:200-1:1000)

  • Optimize incubation conditions (time, temperature)

  • For IHC applications, validated dilutions range from 1:200 to 1:500

• Validation controls:

  • Include POPDC2 knockout tissue as negative control

  • Pre-adsorb antibody with immunizing peptide

  • Include isotype control at same concentration as primary antibody

What are the critical factors for successful POPDC2 protein extraction from heart tissue?

For successful POPDC2 protein extraction from heart tissue:

Tissue preparation:

• Rapidly excise heart tissue and snap-freeze in liquid nitrogen

• Pulverize frozen tissue with pre-cooled pestle and mortar to ensure complete homogenization

• Maintain cold chain throughout preparation to minimize protein degradation

Lysis conditions:

• Use 1% (v/v) Triton X-100-based lysis buffer supplemented with protease inhibitor cocktail

• Include phosphatase inhibitors if studying phosphorylation status

• Consider adding cAMP analogs (e.g., 8-Br-cAMP) if studying cAMP-dependent interactions

• Sonicate lysates thoroughly to ensure complete membrane solubilization

• Centrifuge for 30 minutes at >16,000 g to remove insoluble material

Protein preservation:

• Add reducing agents immediately before gel loading (not during storage)

• For complex detection, consider milder conditions: 4 M urea and 10% (w/v) SDS without reducing agent has been successful for detecting POPDC complexes

• For POPDC protein complexes, some protocols recommend sample incubation at 37°C for 30 minutes rather than boiling, which may preserve protein-protein interactions